EANM Procedure Guidelines for Other Radionuclide TherapiesOn this page you will find links to some European Association of Nuclear Medicine (EANM) Procedure Guidelines relating to other radionuclide therapies.
Please follow the links below to the desired applications.
- EANM Procedure Guidelines for I-131- Ethiodised Oil (Lipiodol) Therapy (2002)
- The purpose of this guideline is to assist nuclear medicine practitioners in evaluating patients who might be candidates for treatment using 131I lipiodol for primary hepatocellular carcinoma, providing information for performing this treatment and understanding and evaluating the sequelae of therapy. Ethiodised oil, also known as Lipiodol is a naturally iodinated fatty acid ethyl ester of poppy seed oil. After hepatic intra-arterial injection, 131I-Lipiodol follows arterial flow towards the tumour and is trapped in tumour microvessels.
- EANM procedure guidelines for I-131-meta-iodobenzylguanidine (131I-mIBG) therapy (2008)
The purpose of this guideline is to assist nuclear medicine practitioners to 1. Evaluate patients who might be candidates for 131I-metaiodobenzylguanidine (mIBG) to treat neuro-ectodermal tumours, 2. Provide information for performing this treatment and 3. Understand and evaluate the consequences of therapy.
Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called “false” neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system.
- EANM procedure guideline for P-32 phosphate treatment of myeloproliferative diseases (2007)
The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for 32P phosphate therapy. It is used for patients with Polycythaemia Vera and Essential thrombocythaemia. 32P is actively incorporated into
the nucleic acids of rapidly proliferating cells. The radiopharmaceutical is used to suppress hyperproliferative cell lines rather than to eradicate them.
- EANM procedure guideline of radio-immunotherapy for B-cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan (Zevalin®) (2006)
The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radioimmunotherapy. EMEA has approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin®, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin´s lymphoma (NHL) in January 2004. Being a pure beta-emitter with a pathlength of 100-200 cell diameters, 90Y has a broad crossfire effect when it is conjugated to monoclonal antibody such as ibritumomab.